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4-Phenylbutyric Acid Treatment Rescues Trafficking
and Processing of a Mutant Surfactant Protein–C
Gareth A. Stewart1*, Ross Ridsdale2*, Emily P. Martin2, Cheng-Lun Na2, Yan Xu2,
Karunyakanth Mandapaka2, and Timothy E. Weaver2
1Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, United Kingdom;
and 2Division of Pulmonary Biology, Cincinnati Children’s Research Foundation, and Department of Pediatrics, University of Cincinnati
College of Medicine, Cincinnati, Ohio
Mutations in the SFTPC gene, encoding surfactant protein–C (SP-C),
are associated with interstitial lung disease (ILD). Knowledge of the
intracellular fateofmutantSP-C is essential in thedesignof therapies
to correct trafficking/processing of the proprotein, and to prevent
the formation of cytotoxic aggregates. We assessed the potential of
a chemical chaperone to correct the trafficking and processing of
three disease-associated mutant SP-C proteins. HEK293 cells were
stably transfected with wild-type (SP-CWT) or mutant (SP-CL188Q,
SP-CΔexon4, or SP-CI73T) SP-C, and cell lines with a similar expression
ofSP-CmRNAwere identified.Theeffectsof thechemical chaperone
4-phenylbutyric acid (PBA) and lysosomotropic drugs on intracellu-
lar trafficking to the endolysosomal pathway and the subsequent
conversion of SP-C proprotein to mature peptide were assessed.
Despite comparable SP-C mRNA expression, proprotein concentra-
tions varied greatly: SP-CI73T was more abundant than SP-CWT and
was localized to the cell surface, whereas SP-CΔexon4 was barely
detectable. In contrast, SP-CL188Q and SP-CWT proprotein concentra-
tions were comparable, and a small amount of SP-CL188Q was local-
ized to the endolysosomal pathway. PBA treatment restored the
trafficking and processing of SP-CL188Q to SP-CWT concentrations,
but did not correct the mistrafficking of SP-CI73T or rescue
SP-CΔexon4. PBA treatment also promoted the aggregation of
SP-C proproteins, including SP-CL188Q. This study provides proof of
the principle that a chemical chaperone can correct the mistraffick-
ing and processing of a disease-associated mutant SP-C proprotein.
Keywords: pulmonary surfactant protein–C; interstitial lung disease;
4-phenylbutyric acid; chemical chaperone
Interstitial lung disease (ILD) is the result of a multiplicity of
pathological processes, from infections to autoimmune diseases
(1). In addition to idiopathic forms of the disease, familial ILD
has also been reported. Mutations in the gene encoding surfac-
tant protein–C (SP-C) are associated with heritable ILD in both
children (2) and adults (1), and are the focus of this study.
SP-C, encoded by the SFTPC gene on chromosome 8 in
humans, is a hydrophobic protein produced by alveolar Type
II epithelial cells. Human SP-C is synthesized as a 197–amino
acid precursor protein (proSP-C) that undergoes multiple pro-
teolytic cleavages as it traffics through the endolysosomal
pathway to the lamellar body. The fully processed 35–amino
acid mature SP-C peptide is packaged with SP-B and phospho-
lipids into bilayer membranes that are stored in lamellar bodies
before secretion into the alveolar airspaces.
Nogee and colleagues described the first disease-associated
SFTPC mutation in an infant and her mother in 2001 (3). An
SFTPC mutation that resulted in the skipping of exon 4 (SP-
CΔexon4) was identified in one allele in both subjects, consistent
with autosomal dominant inheritance. A number of other auto-
somal dominant SFTPC mutations were subsequently identified
with a range of histological phenotypes, even within kindreds.
For example, a mutation leading to the substitution of glutamine
for leucine at position 188 of proSP-C (SP-CL188Q) resulted in
a variable disease onset, with nonspecific interstitial pneumonia
(NSIP) in children and usual interstitial pneumonia (UIP) in
adults of the same family (4, 5).
Very little is known about the pathogenesis of lung disease as-
sociated with SFTPC mutations. The overexpression of mutant
proSP-C can cause cytotoxicity in transfected cells (4) and trans-
genic mice (6). However, not all individuals who carry a disease-
associated mutant SFTPC allele are symptomatic (4, 5). This
observation led to the hypothesis that misfolded proSP-C is nor-
mally rapidly degraded but, under specific conditions (e.g., viral
infection), might accumulate to form cytotoxic aggregates that, in
turn, could trigger disease onset (7). In this model of disease
pathogenesis, the goal of therapy would involve accelerating
the turnover of the misfolded proprotein to prevent aggregation.
This therapeutic approach comes at the expense of reduced SP-C
in the airspaces. An alternative approach would involve the res-
cue of misfolded proprotein by promoting folding to a stable
conformation that will pass quality control in the endoplasmic
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CLINICAL RELEVANCE
Mutations in the gene encoding surfactant protein–C
(SFTPC) are associated with interstitial lung disease in
both children and adults. The pathogenesis is thought to
be related to an accumulation of cytotoxic aggregates of
misfolded surfactant protein–C proprotein (proSP-C). No
treatment options are currently available. Treatment with
4-phenylbutyric acid (PBA) rescues at least one form of
mutant proSP-C from proteasome degradation, and restores
trafficking to the endolysosomal pathway as well as the con-
version of the proprotein to the mature peptide. This study
shows that PBA may be a viable treatment option for some
patients with SFTPC mutations.
reticulum (ER) and traffic to the endolysosomal pathway for
processing to the mature peptide.
Chemical chaperones are small molecules that promote the
stabilization and folding of nascent proteins (8). The chemical
chaperone 4-phenylbutyric acid (PBA) has been shown to res-
cue the trafficking of a wide range of misfolded proteins, includ-
ing the ATP-binding cassette (ABC) transporters ABCC6 (9)
and ABCC7/cystic fibrosis transmembrane conductance regula-
tor (10). PBA is one of only two chemical chaperones currently
approved by the United States Food and Drug Administration
for use in humans. The present study evaluated the potential of
PBA to restore the trafficking and processing of three different
mutant SP-C proproteins. The most common SFTPC allele as-
sociated with ILD in both pediatric and adult patients is a sub-
stitution of threonine for isoleucine at position 73 of proSP-C
(SP-CI73T) (11–13). This mutation occurs in a highly conserved
region of the linker domain, a 34 amino acid juxtamembrane
portion of the C-terminal (luminal) region of the proprotein. In
contrast, the SP-CΔexon4 and SP-CL188Q mutations are located in
the 105–amino acid, C-terminal Brichos domain, a region to
which the majority of SFTPC mutations map. The Brichos do-
main functions as an intramolecular chaperone for the meta-
stable transmembrane domain of the proprotein (14–16).
Disease-associated Brichos mutations are thought to compro-
mise chaperone activity, leading to terminal misfolding and the
proteasomal degradation of the proprotein via the ER-associated
degradation (ERAD) pathway.
In this study, we used cell lines that stably (constitutively) ex-
press nontagged SP-CWT, SP-CI73T, SP-CL188Q, or SP-CΔexon4
(7, 17) to avoid artifacts associated with the transient overex-
pression or tagging of SP-C proproteins. The stability of each
mutant proprotein and its ability to traffic to the endolysosomal
pathway for processing to mature peptide were evaluated in the
presence or absence of chemical chaperones and lysosomo-
tropic drugs. The results demonstrate for the first time, to the
best of our knowledge, that PBA at clinically achievable and
tolerable concentrations can rescue SP-CL188Q from ERAD,
and restore both trafficking and processing of the proprotein
to its mature peptide. A portion of these studies was previously
reported in abstract form (18).
MATERIALS AND METHODS
Reagents
PBA, chloroquine, formic acid, brefeldin A, and glycerol were pur-
chased from Sigma (St. Louis, MO). Bafilomycin A1 was purchased
from Calbiochem (San Diego, CA). Antibodies directed against the
N-terminal propeptide of SP-C or the mature SP-C peptide were ob-
tained from Seven Hills Bioreagents (Cincinnati, OH). The genera-
tion of the antibody directed against the C-terminal (luminal) domain
of SP-C was previously described (16).
Generation of Stably Transfected Lines
Full-length human wild-type (SP-CWT) or mutant (SP-CL188Q, SP-CΔexon4,
or SP-CI73T) SP-C was subcloned into pTRE2-Hyg (Clontech, Mountain
View, CA), and stably transfected cell lines were generated in HEK293
Tet-Off cells, as previously described (7).
Analyses of SP-C mRNA and Protein Expression
SDS-soluble and insoluble proteins were isolated, normalized to the
total cell lysate protein concentration, and analyzed by SDS-PAGE/
Western blotting, as previously described (6, 7, 15). Pulse-chase experi-
ments were performed as previously described (17). The isolation of
RNA for quantitative PCR and microarray analyses is described in the
online supplement. Unfolded protein response element luciferase reporter
assays and confocal microscopy were performed exactly as previously
described (7, 19). Immunogold labeling and ultrastructural analyses
of HEK293 cells are described in the online supplement.
Statistical Analysis
All experiments were performed at least three times, except where noted.
Datawere analyzedusingGraphPadPrism, version 5.0 (GraphPadSoftware,
Inc., La Jolla, CA). The data are representative of at least three independent
transfection experiments, with each group performed in triplicate. Data are
plotted as means6 SD, and were analyzed by the Tukey multiple compar-
isons test. Statistical significance was defined as P , 0.05.
RESULTS
SFTPC Mutations Result in Widely Variable
Proprotein Stability
Except where noted, all experiments in this study were performed
in stably transfected HEK293 cells to model the constitutive ex-
pression of SP-C. Multiple cell lines stably expressing untagged
SP-CWT or mutant SP-C (SP-CI73T, SP-CL188Q, or SP-CΔexon4)
were grown in the absence of doxycycline to induce the expres-
sion of the proprotein, and screened to identify four cell lines that
expressed similar concentrations of SP-C mRNA (Figure 1A).
Cell lysates (30 mg) of each line were subsequently immunoblot-
ted with antibodies directed against the N-terminus of the SP-C
proprotein or the mature SP-C peptide, to assess relative protein
expression (Figure 1B). Despite comparable SP-C mRNA con-
centrations, proSP-C expression varied greatly among the four
cell lines (Figure 1B). SP-CWT proprotein was considerably more
abundant than SP-CΔexon4 proprotein, which was previously
shown to be rapidly degraded by the proteasome (7, 17).
SP-CL188Q mutant proprotein was also more stable than SP-CΔexon4
proprotein and similar to SP-CWT proprotein. Notably, SP-CI73T
proprotein accumulated to a much greater extent than either
SP-CWT or the other two mutant proproteins. The abundance
of the SP-CI73T mutant was particularly striking when all forms
of the proprotein were considered, including two unique bands
recently identified by Beers and colleagues (20), composed of
a prominent processing intermediate (Figure 1B, white arrow-
head) and a slower-migrating form of the proprotein (Figure
1B, black arrowhead, and Figure 2C). Thus the stability of
proSP-C varies widely with the mutation: SP-CI73T accumu-
lates, SP-CΔexon4 is rapidly degraded, and SP-CL188Q exhibits
an intermediate stability similar to that of SP-CWT.
The expression of SP-CWT in cells lacking lamellar bodies,
such as HEK293 cells, results in the anterograde trafficking of
the proprotein to the lysosome, where it is processed to the ma-
ture peptide (19) (Figure 1B, center). In contrast, the SP-CL188Q
and SP-CΔexon4 mutants are ERAD substrates that are retained in
the ER and degraded by the proteasome (17). The Western blot-
ting of cell lysates detected a small amount of mature peptide
in cells stably expressing SP-CL188Q, suggesting that some of the
proprotein escaped ER quality control when constitutively
expressed in HEK293 cells (Figure 1B, center). No mature pep-
tide was identified in cells expressing SP-CΔexon4 or SP-CI73T,
although longer exposure of the blot detected some mature
peptide in cells expressing SP-CI73T (not shown).
The block in processing of the SP-CI73T proprotein to the
mature peptide, coupled with the accumulation of proprotein,
suggested that the I73T mutation may impart increased stability
to the proprotein. To test this hypothesis, pulse-chase experi-
ments were performed in HEK293 cells stably expressing WT or
mutant SP-C. SP-CWT was synthesized as a proprotein (Figure
2A, band 1) that was posttranslationally modified to a larger
proprotein (Figure 2A, band 2), with an estimated t1/2 of 145
minutes. The conversion of band 1 to band 2 was incomplete and
blocked by brefeldin A (Figure E1A in the online supplement),
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consistent with proprotein modification in a compartment distal
to the ER. In contrast, very little SP-CL188Q was converted to
band 2 and the proprotein was rapidly degraded, with a t1/2 of 43
minutes (Figure 2B). Band 1 of SP-CI73T was rapidly converted
to band 2 and a higher molecular weight protein (Figure 2C,
band 3). The formation of band 3 was inhibited by brefeldin A
(Figure E1B) or by the mutation of isoleucine at position 73 to
serine (I73S) or lysine (I73K) (Figure E1C). Both bands 2 and 3
of SP-CI73T were very stable and did not decrease over the 2-
hour chase period (Figure 2C). Thus the I73T mutation is asso-
ciated with decreased proprotein processing/degradation that
leads to accumulation.
PBA Treatment Stabilizes SP-C Proprotein and Promotes
Conversion to Mature Peptide
To determine if chemical chaperones would promote processing
of the mutant proproteins to the mature peptide, cell lines were
treated with PBA or glycerol. PBA was added at up to 2.5 mM
and glycerol at up to 2.5% (higher doses of either reagent result
in toxicity in all cell lines), and the cell lysates were probed for
both proSP-C and mature SP-C. Because glycerol treatment did
not alter SP-C concentrations, only the PBA data are reported
here. PBA treatment did not significantly alter concentrations of
SP-CWT proprotein or mature peptide (Figure 3A). In contrast,
PBA treatment promoted a significant accumulation of
SP-CL188Q and SP-CΔexon4 proproteins (Figure 3A, top). Propro-
tein stabilization was accompanied by a corresponding increase
in mature peptide in cells expressing SP-CL188Q but not SP-CΔexon4
(Figure 3A, center). Although PBA did not alter SP-CI73T pro-
protein concentrations, treatment was associated with a small
but significant increase in mature peptide. However, the
proprotein/mature peptide ratio remained much higher for
SP-CI73T than for SP-CL188Q or SP-CWT, consistent with the
hypothesis that generation of the mature peptide is partly
blocked in cells expressing SP-CI73T. Overall, PBA treatment
resulted in the stabilization of the SP-CL188Q proprotein and con-
version to mature peptide at concentrations approximating those
of SP-CWT. Importantly, the effect of PBA was reproduced in
three different HEK293 cell lines stably expressing SP-CL188Q
(Figure E2A), as well as in mouse lung epithelial (MLE-12) cells
transiently transfected with SP-CL188Q (Figure E2B).
The accumulation of mutant protein is frequently associated
with the induction of ER stress. In this study, no evidence of
ER stress was detected in any of the untreated SP-C cell lines (Fig-
ure 3B), consistent with our previous finding that the constitutive/
stable expression of SP-CΔexon4 in HEK293 cells is not accompa-
nied by ER stress (7). The absence of ER stress in cells expressing
SP-CI73T suggested that the proproteinmight accumulate in a com-
partment outside the ER (to be described later). PBA treatment
resulted in ER stress in cells stably expressing SP-CL188Q, but not
in cells expressing SP-CWT or either of the other two mutant
proproteins (Figure 3B). PBA-induced ER stress (Figure 3B)
may be related to the stabilization and retention of the proprotein
in the ER that, in turn, allows more time for folding.
PBA Treatment Induces Detergent-Insoluble Aggregates
of SP-C Proprotein
Mutant proSP-C has a high propensity to form intracellular SDS-
insoluble aggregates. To assess aggregate formation, lysates of
cells stably expressing SP-CWT or mutant SP-C were extracted
Figure 1. Variable expression
of mutant surfactant protein–
C proprotein (proSP-C). (A)
HEK293 cell lines stably
expressing SP-CWT, SP-CI73T,
SP-CL188Q, or SP-CΔexon4 were
screened by quantitative RT-
PCR to identify lines that
expressed similar concentra-
tions of SP-C mRNA. (B) Cell
lines were grown in the ab-
sence of doxycycline to induce
the expression of SP-C. Cell
lysates (30 mg) were analyzed
by SDS-PAGE, followed by
Western blotting. Blots were
sequentially probed with anti-
body directed against mature
SP-C peptide (middle), proSP-
C (left), and actin (right). The
detection of SP-CΔexon4 re-
quired extended exposure of
the blot for proSP-C (left).
Unique forms of SP-CI73T pro-
protein (black arrowhead) and
processing intermediate (white
arrowhead) are indicated. WT,
wild-type.
326 AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY VOL 47 2012
with 1% SDS, and the detergent-insoluble fractions were analyzed
by Western blotting. High molecular weight (. 250 kD) SP-C
aggregates were consistently detected in SDS-insoluble fractions
of all four cell lines, indicating that both mutant and WT SP-C
can aggregate (Figures 4A and 4B). In the absence of PBA treat-
ment, SDS-insoluble SP-C proprotein was much more abundant
in cells expressing SP-CI73T (Figure 4A) compared with cells ex-
pressing SP-CWT, SP-CL188Q (Figures 4A and 4B), or SP-CΔexon4
proprotein (Figure 4B, right). We note that the aggregates were
located at the top of the gels, leaving open the possibility that
not all the sample entered the gel, leading to an underestima-
tion of the amount of SDS-insoluble SP-C. These data indicate
that SP-CI73T is the most aggregate-prone of the three mutant
proteins tested in this study, and that the total amount of
SP-CI73T proprotein (detergent-soluble 1 detergent-insoluble)
is greater than initially estimated (Figure 1B). Treatment with
PBA promoted the accumulation of SDS-insoluble SP-C aggre-
gates in a dose-dependent manner. This effect was most pro-
nounced for SP-CL188Q, but was also apparent for SP-CWT and
SP-CΔexon4 after the extended exposure of Western blots (Figure
4B). At the highest dose of PBA, the amount of detergent-
insoluble SP-CL188Q was similar to that observed for SP-CI73T
proprotein (Figure 4A). Thus PBA treatment increases both sol-
uble and insoluble forms of SP-CL188Q.
SP-CI73T and SP-CL188Q Traffic through Distinct
Intracellular Pathways
The detection of mature peptide in cells expressing SP-CWT or
SP-CL188Q (Figure 1) is consistent with the trafficking of these
proproteins to the endolysosomal pathway. Treatment with the
lysosomotropic drugs bafilomycin A1 (Figure 5) or chloroquine
(not shown) resulted in the accumulation of proprotein and
inhibited the conversion to mature peptide, further supporting
this conclusion. Treatment with azithromycin, a drug recently
shown to inhibit lysosomal acidification (21), produced similar
effects on proprotein stabilization and processing (not shown).
In contrast, SP-CI73T proprotein was not affected, and the ma-
ture peptide was barely detectable. This result suggests that,
unlike SP-CWT and SP-CL188Q, relatively little SP-CI73T propro-
tein traffics to the lysosome. Treatment with lysosomotropic
drugs also exerted no effect on SP-CΔexon4, likely because this
proprotein is rapidly degraded by the proteasome and is not
exported from the ER.
The differential response of SP-CL188Q and SP-CI73T to PBA
and lysosomotropic drugs likely reflects distinct intracellular
trafficking patterns for the two mutant proproteins. Unlike
SP-CL188Q, SP-CI73T did not accumulate in response to protea-
some inhibition (not shown), and did not engage the ERAD
chaperones endoplasmic reticulum–localized DnaJ homologue
4 (ERdj4) or ERdj5 (Figure E3A). Further, unlike SP-CΔexon4,
the transient expression of SP-CI73T did not induce ER stress
(Figure E3B). These data, coupled with the finding that brefeldin
A blocks the formation of band 3 in SP-CI73T (Figure E1B),
indicate that SP-CI73T passes ER quality control, resulting in
rapid export to the Golgi apparatus. Confocal microscopy with
an antibody directed against the C-terminal (luminal) domain of
proSP-C confirmed that SP-CI73T colocalized with wheat germ
agglutinin (WGA) at the surface of nonpermeabilized cells
(Figure 6), as recently reported (20). Immunogold labeling fur-
ther confirmed the cell-surface localization of SP-CI73T and the
absence of proprotein on the surface of cells expressing SP-CWT
(Figure E4). Little or no colocalization of SP-C with WGA was
detected in cells expressing SP-CWT, SP-CL188Q, or SP-CΔexon4
(Figure 6). To assess the turnover of cell-surface SP-C, cells
stably expressing SP-CI73T were grown in the presence of doxy-
cycline to suppress the expression of SP-C. Confocal microscopy
confirmed the extended residency of SP-CI73T at the cell surface
Figure 2. Differential stability of mutant SP-C proproteins.
SP-CWT (A), SP-CL188Q (B), and SP-CI73T (C) cell lines were
grown in the absence of doxycycline. Cells (2.5 3 106
cells/well of a six-well plate) were labeled with 35(S) cys-
teine/methionine for 10 minutes, followed by transfer to
chase media for the indicated periods of time. Cell lysates
were immunoprecipitated with antibody directed against
proSP-C, and analyzed by SDS-PAGE/autoradiography.
Densitometric analyses appear to the right of each image.
The sum of proSP-C bands 1 and 2 is plotted for SP-CWT
(A) and SP-CL188Q (B).
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(Figure E5). These results suggest that an accumulation of SP-CI73T
in the plasma membrane likely accounts for the unusual stabil-
ity of the proprotein and the inhibition of proprotein conversion
to mature peptide.
DISCUSSION
In this study, we used the stable expression of constructs encod-
ing WT or mutant SP-C to model the constitutive expression of
SP-C in vivo. The selection of cell lines that express similar
concentrations of SP-C mRNAs revealed that proprotein stabil-
ity varied widely with the SFTPC mutation. Unexpectedly, both
detergent-soluble and insoluble forms of SP-CI73T accumulated to
a much greater extent than did the Brichos mutants, SP-CL188Q
and SP-CΔexon4. SP-CI73T proprotein did not engage the ERAD
chaperones previously reported to be involved in the turnover
of Brichos mutants (17) or induce ER stress, as previously noted
by Mulugeta and colleagues (22). These data, coupled with the
results of pulse-chase experiments, suggest that SP-CI73T does
not accumulate in the ER, but rather is rapidly folded and
exported from the ER to the Golgi apparatus. For this reason,
PBA treatment, which promotes the folding of some protein
substrates in the ER, exerted no effect on SP-CI73T. Confocal
microscopy detected SP-CI73T at the plasma membrane, con-
firming a recent report by Beers and colleagues (20). The loss
of SP-CI73T from the plasma membrane occurred slowly, sug-
gesting that cell-surface localization accounts for much of the
accumulated proprotein. Consistent with this idea, relatively
little proprotein was processed to mature peptide, an event that
occurs in the endolysosomal pathway. Further, lysosomotropic
drugs did not cause an accumulation of SP-CI73T proprotein.
Collectively, these data suggest that the trafficking of SP-CI73T
to the plasma membrane occurs rapidly, but that internalization
and routing to the lysosome for processing/degradation consti-
tute much slower events. Overall, the development of therapies
for this “common” SFTPC mutation will require a better un-
derstanding of the molecular basis for SP-CI73T mistrafficking.
In contrast to SP-CI73T, SP-CΔexon4 was the least stable of the
mutant proproteins, and frequently required an overexposure of
Figure 4. PBA promotes the formation of detergent-insoluble SP-C
aggregates. (A) Cell lines were grown in the absence of doxycycline
and treated with PBA for 48 hours. SDS-insoluble protein was isolated
from equivalent amounts of cell lysates and analyzed by SDS-PAGE,
followed by Western blotting with proSP-C antibody. (B) To detect
detergent-insoluble SP-CWT, the experiment in A was repeated, and
exposure times for blots were increased (left). The detection of
SP-CΔexon4 required the longest exposure times (right).
Figure 3. 4-phenylbutyric acid
(PBA) promotes SP-C propro-
tein stabilization and process-
ing. (A) Cell lines were grown
in the absence of doxycycline
and treated with PBA for
48 hours. Cell lysates (30 mg)
were analyzed by SDS-PAGE/
Western blotting. Blots were
sequentially probed with anti-
body directed against proSP-C
(top), mature SP-C peptide
(middle), and actin (bottom).
The quantitation of the effects
of PBA on proSP-C and mature
peptide are shown to the right
(n ¼ 3). (B) Cell lines were
grown in the absence of doxycy-
cline and transiently transfected
with plasmids encoding un-
folded protein response ele-
ment (UPRE) reporter and
pRL-TK (plasmid expressing
Renilla Luciferase under the
herpes simplex virus thymi-
dine kinase promoter). Cells
were harvested 48 hours later,
and luciferase activity was mea-
sured using the dual-luciferase
reporter assay system (Prom-
ega). Data are plotted as ratios
of Firefly/Renilla activity to cor-
rect for transfection efficiency.
*P , 0.05. **P , 0.001.
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immunoblots to detect its signal (Figure 1B). This result is in
marked contrast to the reported tendency of SP-CΔexon4 to form
aggresomes (23), a property that may well be related to the tran-
sient overexpression and saturation of the disposal pathway. The
robust overexpression of SP-CΔexon4 in Type II epithelial cells of
transgenic mice resulted in aggregation, cytotoxicity, and lung dys-
morphogenesis (6). In the present study, the constitutive expression
of SP-CΔexon4 at concentrations that did not induce ER stress
resulted in the formation of very little detergent-insoluble propro-
tein, particularly when compared with SP-CI73T. PBA treatment
increased the amount of SP-CΔexon4 proprotein, but the concentra-
tion was still much lower than for SP-CWT, and was not accompa-
nied by detectable processing to the mature peptide. Moreover,
treatment with bafilomycin A1, chloroquine, or azithromycin did
not cause proprotein accumulation, suggesting that little or no
SP-CΔexon4 was trafficked to the endolysosomal pathway. Protea-
some inhibition resulted in a robust accumulation of proprotein
(7) and a stable association with ER chaperones (Figure E3A),
confirming that SP-CΔexon4 is a canonical ERAD substrate. Taken
together, these results suggest that this SFTPC mutation leads to
severe misfolding, and that the rescue of the mutant proprotein
by treatment with chemical chaperones will be very challenging.
Like SP-CΔexon4, SP-CL188Q is also an ERAD substrate (Fig-
ure E3A) (17). The constitutive expression of SP-CL188Q at con-
centrations that did not cause ER stress resulted in the
trafficking of some proprotein to the endolysosomal pathway,
as indicated by our detection of mature peptide and the accu-
mulation of proprotein in response to bafilomycin A1, chloro-
quine, or azithromycin. Treatment with concentrations of PBA
widely used in other in vitro studies (10, 24–26) promoted the
export of SP-CL188Q from the ER, leading to increased propro-
tein concentrations and the enhanced conversion of proprotein
to mature peptide. At a dose of 1 mM PBA, the mature peptide
concentration in SP-CL188Q–expressing cells approximated that
in SP-CWT cells, with a minimal aggregation of proprotein. This
dose is similar to that used in two clinical trials in which the
concentration of PBA in serum ranged from 0.04–2.0 mM (27,
28). Collectively, these results suggest that this SFTPCmutation
Figure 5. Trafficking of SP-C to the Golgi ap-
paratus and endolysosomal compartments.
(A) Cell lines were gown in the absence of
doxycycline and treated with bafilomycin A1
for 24 hours. Cell lysates (30 mg) were ana-
lyzed by SDS-PAGE/Western blotting. Blots
were sequentially probed for proSP-C (top),
mature SP-C peptide (middle), and actin
(bottom). (B) Quantitation of the effects of
bafilomycin A1 on proSP-C (n ¼ 3) and ma-
ture peptide concentrations (n ¼ 2).
Figure 6. SP-CI73T is localized to the cell surface. Cells
were grown on coverslips in the absence of doxycycline,
fixed in situ with 4% paraformaldehyde, and processed for
confocal microscopy without permeabilization. Cells were
incubated with antibody directed against the C-terminus
of proSP-C (top row) or wheat germ agglutinin (WGA) to
label the cell surface (middle row). No signal was detected
when cells were incubated with antibody directed against
the N-terminus of proSP-C, confirming that the Brichos
domain is extracellular (not shown).
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is amenable to rescue by PBA, and may offer a viable treatment
option for patients.
The results of the present study provide support for the screen-
ing of other Brichos domain mutants to determine which mutants
may be amenable to PBA therapy. However, this study also
underscores the need for further investigation of the long-term
effects of PBA treatment. PBA caused an increase in SDS-
insoluble proprotein in cells expressing SP-CL188Q. Mutant
proSP-C, including SP-CL188Q, can form amyloid-like fibrils (15)
related to the loss of chaperone activity of the Brichos domain
(14, 29) and subsequent transition of the a-helical transmem-
brane domain to a b-sheet structure (30, 31). Artificial b-sheet
proteins that form amyloid-like fibrils have been shown to se-
quester proteins required for critical cellular functions (32). In
the present study, the accumulation of SDS-insoluble proprotein
was not associated with cytotoxicity (data not shown). However,
the effect of extended PBA treatment on SP-CL188Q aggregation/
cytotoxicity remains to be evaluated. Overall, analyses of PBA
treatment in mice expressing SP-CL188Q (currently in develop-
ment) will provide important insight into the risks and benefits
of this potential therapy.
In conclusion, PBA treatment substantially restored intracel-
lular trafficking and processing of the SP-CL188Q proprotein to its
mature peptide. Whether this correction will be sufficient to
prevent or slow pathogenesis remains to be established, as do
any potential adverse effects of prolonged PBA treatment. Given
the propensity of all SP-C proproteins, including SP-CWT, to form
detergent-insoluble aggregates, the use of drugs promoting the
simultaneous proprotein stabilization and inhibition of process-
ing, such as chloroquine and azithromycin (33, 34), should be
carefully reevaluated.
Author disclosures are available with the text of this article at www.atsjournals.org.
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